CN110099686B - 非酒精性脂肪性肝病的治疗 - Google Patents

非酒精性脂肪性肝病的治疗 Download PDF

Info

Publication number
CN110099686B
CN110099686B CN201780062867.1A CN201780062867A CN110099686B CN 110099686 B CN110099686 B CN 110099686B CN 201780062867 A CN201780062867 A CN 201780062867A CN 110099686 B CN110099686 B CN 110099686B
Authority
CN
China
Prior art keywords
compound
dose
administered
day
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780062867.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110099686A (zh
Inventor
G·哈纳尤尔
H·纳加布库罗
Y·阿马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda GmbH
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH, Takeda Pharmaceutical Co Ltd filed Critical Takeda GmbH
Publication of CN110099686A publication Critical patent/CN110099686A/zh
Application granted granted Critical
Publication of CN110099686B publication Critical patent/CN110099686B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780062867.1A 2016-08-26 2017-08-25 非酒精性脂肪性肝病的治疗 Active CN110099686B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380004P 2016-08-26 2016-08-26
US62/380,004 2016-08-26
PCT/EP2017/071418 WO2018037109A1 (en) 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CN110099686A CN110099686A (zh) 2019-08-06
CN110099686B true CN110099686B (zh) 2022-04-15

Family

ID=59699703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780062867.1A Active CN110099686B (zh) 2016-08-26 2017-08-25 非酒精性脂肪性肝病的治疗

Country Status (7)

Country Link
US (1) US11179384B2 (enExample)
EP (1) EP3503892A1 (enExample)
JP (1) JP7048863B2 (enExample)
CN (1) CN110099686B (enExample)
AU (1) AU2017317575B2 (enExample)
CA (1) CA3034956C (enExample)
WO (1) WO2018037109A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1261331A4 (en) * 2000-02-16 2005-01-05 Univ Nebraska Medical Ct METHOD AND COMPOSITIONS FOR TREATING FIBROSANT DISEASES
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
CN101133045A (zh) * 2005-03-02 2008-02-27 尼科梅德有限责任公司 6-杂环基取代的六氢菲啶衍生物的新盐类
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.
MEP8509A (en) * 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
WO2015110394A1 (en) * 2014-01-22 2015-07-30 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
WO2015200177A1 (en) * 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2017017165A1 (en) * 2015-07-29 2017-02-02 Takeda Gmbh Pde4 inhibitor for the treatment of diabetic nephropathy

Also Published As

Publication number Publication date
JP2019524860A (ja) 2019-09-05
US20210283122A1 (en) 2021-09-16
AU2017317575B2 (en) 2021-10-14
WO2018037109A1 (en) 2018-03-01
US11179384B2 (en) 2021-11-23
EP3503892A1 (en) 2019-07-03
JP7048863B2 (ja) 2022-04-06
CN110099686A (zh) 2019-08-06
CA3034956C (en) 2024-10-29
CA3034956A1 (en) 2018-03-01
AU2017317575A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
CA3019496A1 (en) Medicine obtained by combining fxr agonist and arb
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN110876751A (zh) 曲美替尼在制备预防和/或治疗非酒精性肝炎和/或非酒精性脂肪性肝病中的应用
JP7756126B2 (ja) 脂肪性肝疾患の治療薬
US20100075937A1 (en) Patient populations and treatment methods
JP2012077084A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
AU2015231076B2 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
JP2021106625A (ja) Ｉｌ−３４アンチセンスオリゴヌクレオチドおよびその使用方法
MX2013001583A (es) Agente profilactico para esteatohepatitis no alcoholica.
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
US11179384B2 (en) Treatment of nonalcoholic fatty liver disease
JP2002523461A (ja) 神経変性疾患の治療方法
RU2849641C1 (ru) Терапевтическое средство против жировой болезни печени
US20260027094A1 (en) Use of pyridone derivative
BR112020004903A2 (pt) uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
HK40089150B (en) Therapeutic agent for fatty liver disease
HK40089150A (en) Therapeutic agent for fatty liver disease
CN121955251A (zh) 牛磺鹅脱氧胆酸作为酒精相关肝病的生物标志物及其防治用途
HK40080642A (zh) 脂肪性肝病的治疗药
AU2024329780A1 (en) Elafibranor for use in the treatment of primary biliary cholangitis
WO2012011572A1 (ja) 拡張不全型心不全治療薬
JP2011219439A (ja) レチノイン酸受容体リガンドによるインスリン抵抗性改善作用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012462

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220111

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Konstanz

Applicant before: TAKEDA GmbH

GR01 Patent grant
GR01 Patent grant